NCT06864936View on ClinicalTrials.gov

Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

March 30, 2027

Study Completion Date

June 30, 2027

Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
DRUG

Ublituximab

ublituximab

OTHER

Other disease modifying therapies

Other disease modifying therapies for MS (not ublituximab)

Trial Locations (1)

21201

University of Maryland, Baltimore, Baltimore

All Listed Sponsors
collaborator

TG Therapeutics, Inc.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT06864936 - Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis | Biotech Hunter | Biotech Hunter